이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized Trial (Hematowellness)

2026년 10월 28일 업데이트: Gruppo Italiano Malattie EMatologiche dell'Adulto

This multicenter, prospective, pilot randomized controlled trial aims to evaluate the feasibility and preliminary efficacy of a 16-week structured exercise program (SEP) in patients with hematologic malignancies, including acute myeloid leukemia, lymphoma, and multiple myeloma.

A total of 75 patients will be randomized in a 1:1 ratio to either a supervised exercise intervention or a control group receiving usual care and general advice on physical activity.

The intervention consists of a personalized, hybrid exercise program combining supervised home- and gym-based training, aerobic and resistance exercises, balance and stretching activities, and behavioral counseling.

The primary objective is to assess the feasibility of the intervention in terms of adherence to the exercise program and patient satisfaction.

Secondary objectives include evaluating intervention-related adverse events, patient-reported burden, health-related quality of life, fatigue, physical fitness, anthropometric parameters, and physical activity levels.

Assessments will be conducted at baseline, approximately 8 weeks, 16 weeks (end of intervention), and 24 weeks after randomization.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

75

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Bari, 이탈리아, 70126
        • 아직 모집하지 않음
        • Irccs Oncologico Istituto Tumori Giovanni Paolo Ii - Bari - Uo Ematologia
        • 연락하다:
      • Verona, 이탈리아, 37134
        • 아직 모집하지 않음
        • Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc Ematologia
        • 연락하다:
    • Rm
      • Roma, Rm, 이탈리아, 00133
        • 모병
        • Fondazione PTV Policlinico Tor Vergata
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

**Inclusion Criteria:**

  1. Patients aged between 18 and 75 years.

  2. ECOG Performance Status ≤2.

  3. Patients discharged after first-line intensive treatments (Category A), including:

    • Acute myeloid leukemia (AML) in clinical remission following first-line intensive treatment (post-consolidation), within 30 days of hospital discharge, and not candidates for transplantation.
    • Multiple myeloma in clinical remission following first-line treatment with autologous stem cell transplantation, within 30 days of hospital discharge.
    • Lymphoma in clinical remission following first-line intensive treatment (e.g., CODOX-M/IVAC, HYPER-CVAD, DA-EPOCH, CHOP/DHAP, with or without autologous stem cell transplantation consolidation), within 30 days of hospital discharge.
  4. Patients receiving or having received first-line treatment in an outpatient setting (Category B), including:

    • Multiple myeloma in complete remission, having completed first-line treatment within the previous 30 days and undergoing maintenance therapy.
    • Lymphoma patients undergoing first-line treatment with at least 12 weeks of therapy remaining.
  5. Written informed consent provided.

**Exclusion Criteria:**

  1. Undergoing monotherapy with monoclonal antibodies.
  2. More than one line of systemic treatment.
  3. Estimated life expectancy of less than 6 months.
  4. Severe neurological illness.
  5. Lack of cardiology clearance or left ventricular ejection fraction below 50%.
  6. Unstable fractures or metastases inducing skeletal fragility, as determined by the treating hematologist, or recent femoral or vertebral fracture (within the previous 12 months).
  7. Serious active infection.
  8. Uncontrolled severe respiratory insufficiency or dependency on oxygen supplementation at rest or during exercise.
  9. Uncontrolled severe pain.
  10. Any other comorbidity contraindicating physical exercise.
  11. Any circumstances preventing adherence to study requirements or the ability to provide informed consent.
  12. Logistical barriers preventing adherence to the exercise program, as judged by the treating hematologist (e.g., distance from training locations, work commitments, or family circumstances).
  13. Regular engagement in physical activity according to current guidelines during the previous 6 months.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Structured Exercise Program (SEP)

Participants randomized to the intervention group will receive a 16-week personalized, supervised, hybrid structured exercise program (SEP), combining home- and gym-based training. The program includes aerobic, resistance, balance, and stretching exercises, a structured walking program, and behavioral counseling. Exercise sessions will be supervised by trained exercise professionals, either in person or remotely, according to the intervention phase.

A 16-week structured and supervised exercise program tailored to the individual patient's clinical condition and physical abilities. The intervention includes aerobic exercise, resistance training, balance and flexibility exercises, walking activities, and behavioral counseling. Exercise sessions may be conducted in person or at home with remote supervision, according to the patient's needs and clinical status.

다른 이름들:
  • upervised Exercise Program (SEP)
간섭 없음: Control

Participants randomized to the control group will receive usual care and general information about the benefits of physical activity. They will not participate in the supervised structured exercise program during the study period.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Adherence to the Structured Exercise Program
기간: At 16 weeks (end of intervention)

Adherence will be assessed as the percentage of participants in the intervention group who attend at least 65% of the planned supervised exercise sessions. The intervention will be considered feasible if at least 70% of participants meet this adherence t

At 16 weeks (end of intervention)
Patient Satisfaction With the Structured Exercise Program
기간: At 16 weeks (end of intervention)

Patient satisfaction will be assessed in the intervention group using the item "Overall, I am satisfied with the exercise program" from a study-specific satisfaction questionnaire. Responses are rated on a 4-point scale: "disagree", "somewhat disagree", "somewhat agree", and "agree". Satisfaction will be measured as the percentage of participants responding "somewhat agree" or "agree". The intervention will be considered feasible if at least 75% of participants meet this satisfaction criterion.

At 16 weeks (end of intervention)

2차 결과 측정

결과 측정
측정값 설명
기간
Change in Health-Related Quality of Life (EORTC QLQ-C30)
기간: Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.

Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Changes in mean scores across all questionnaire scales will be compared between and within study groups. Scores are transformed to a 0-100 scale, with higher scores indicating better functioning or global health status on functional and global health scales, and greater symptom burden on symptom scales.

Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
Change in Fatigue (FACIT-Fatigue)
기간: Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.

Fatigue will be assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire. Changes in mean fatigue scores will be compared between and within study groups at baseline, 8 weeks, and 16 weeks. Fatigue will also be assessed at 24 weeks for descriptive follow-up analyses.

Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
Study Engagement Rate
기간: During the 18-month recruitment period.

The engagement rate will be calculated as the percentage of patients who agree to participate in the study among all patients invited to participate. Reasons for refusal will be documented to identify potential barriers to study participation.

During the 18-month recruitment period.
Incidence of Intervention-Related Adverse Events
기간: Throughout the 16-week intervention period.

The number and severity of adverse events potentially related to the structured exercise program will be assessed in the intervention group. Adverse events will be monitored and recorded by exercise professionals and study personnel throughout the intervention period. Severity will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

Throughout the 16-week intervention period.
Patient-Reported Burden of the Intervention (FACT-G Item GP5)
기간: At 8 weeks (T1) and 16 weeks (T2) after randomization.

Patient-Reported Burden of the Intervention (FACT-G Item GP5)

At 8 weeks (T1) and 16 weeks (T2) after randomization.
Change in Physical Activity Levels (Godin-Shephard Questionnaire)
기간: Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.

Changes in physical activity levels will be assessed using the Godin-Shephard Leisure-Time Physical Activity Questionnaire, which evaluates the frequency of mild, moderate, and vigorous physical activity performed during leisure time. Changes will be compared between and within study groups.

Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
Non-Hematological Adverse Events
기간: Throughout the 16-week intervention period.

The prevalence of non-hematological adverse events of grade 3 or higher will be described and compared between the intervention and control groups. Adverse event severity will be classified according to CTCAE version 5.0.

Throughout the 16-week intervention period.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 10일

기본 완료 (추정된)

2028년 9월 15일

연구 완료 (추정된)

2028년 11월 10일

연구 등록 날짜

최초 제출

2026년 10월 28일

QC 기준을 충족하는 최초 제출

2026년 10월 28일

처음 게시됨 (실제)

2026년 11월 3일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 28일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • GIMEMA QoL-Hematowellness

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .